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Abstract
Alzheimer’s disease (AD) afflicts around 20 million people worldwide and so there is an urgent need for effective treatment.
Our research showing that herpes simplex virus type 1 (HSV1) is a risk factor for AD for the brains of people who possess a
specific genetic factor and that the virus causes accumulation of key AD proteins (b-amyloid (Ab) and abnormally
phosphorylated tau (P-tau)), suggests that anti-HSV1 antiviral agents might slow AD progression. However, currently
available antiviral agents target HSV1 DNA replication and so might be successful in AD only if Ab and P-tau accumulation
depend on viral DNA replication. Therefore, we investigated firstly the stage(s) of the virus replication cycle required for Ab
and P-tau accumulation, and secondly whether antiviral agents prevent these changes using recombinant strains of HSV1
that progress only partly through the replication cycle and antiviral agents that inhibit HSV1 DNA replication. By
quantitative immunocytochemistry we demonstrated that entry, fusion and uncoating of HSV1, are insufficient to induce Ab
and P-tau production. We showed also that none of the ‘‘immediate early’’ viral proteins is directly responsible, and that Ab
and P-tau are produced at a subsequent stage of the HSV1 replication cycle. Importantly, the anti-HSV1 antiviral agents
acyclovir, penciclovir and foscarnet reduced Ab and P-tau accumulation, as well as HSV1, with foscarnet being less effective
in each case. P-tau accumulation was found to depend on HSV1 DNA replication, whereas Ab accumulation was not. The
antiviral-induced decrease in Ab is attributable to the reduced number of new viruses, and hence the reduction in viral
spread. Since antiviral agents reduce greatly Ab and P-tau accumulation in HSV1-infected cells, they would be suitable for
treating AD with great advantage unlike current AD therapies, only the virus, not the host cell, would be targeted.
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Introduction
Alzheimer’s disease (AD) is a prevalent neuropsychiatric
disorder that primarily affects the elderly. It is characterised by
memory loss and cognitive dysfunction, and examination of
sufferers’ brains reveals an abundance of two neuropathological
features – senile plaques and neurofibrillary tangles. Plaques and
tangles, and their components – b-amyloid (Ab) and abnormally
phosphorylated tau (P-tau), respectively – are thought to be central
to disease pathogenesis but their cause and thus the underlying
cause of AD is unknown.
Current treatments for AD are merely palliative and thus there
is an urgent need for medications that delay disease progression.
One possible treatment strategy is the use of antiviral agents, in
particular agents that are effective against herpes simplex virus
type 1 (HSV1). This suggestion is based on the increasing body of
evidence implicating HSV1 in the aetiology of AD.
HSV1 is a neurotropic virus that infects most humans. It is
responsible for a number of diseases including herpes labialis (cold
sores), herpes simplex encephalitis (HSE) and some cases of genital
herpes. The first suggestion that HSV1 might have a role in AD
was based on the observation that in HSE the brain regions
damaged are the same ones as those that are affected in AD [1].
Subsequent research demonstrated that the virus is present in the
brain of most elderly subjects, including AD sufferers, and that it is
present within the brain regions affected by AD [2]. Moreover, the
virus was found to be a risk factor for the disease when in brain of
possessors of a specific genetic factor – the type 4 allele of the
apolipoprotein E gene [3–5]. Additional studies have linked HSV1
directly to the neuropathological features of AD. Specifically,
HSV1 infection of cells in culture causes Ab and P-tau
accumulation [6–12] and the brains of HSV1-infected mice
exhibit Ab deposits [7]. Consistently, the enzymes involved in the
generation of Ab and of (P-tau are increased in HSV1-infected
cells [6,7,13]. Further, the distribution of HSV1 DNA in human
brains in relation to senile plaques has been investigated using a
combination of in situ polymerase chain reaction (which amplifies
and thereby detects low levels of target DNA sequences in tissues)
with immunohistochemistry for Ab, or thioflavin S staining for
plaques. This revealed that HSV1 DNA is located very specifically
within senile plaques in AD frontal and temporal cortex [14]. The
in situ polymerase chain reaction findings do not prove HSV1-AD
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they suggest that HSV1 is involved in formation of plaques (and
toxic Ab oligomers), and hence support a causal role for in AD.
As mentioned above, the role of HSV1 in AD points to the use
of antiviral agents to slow the progression of the disease. However,
currently available antiviral agents target viral DNA replication
and so might only be effective in AD if the accumulation of Ab and
P-tau depends on viral DNA replication. If, on the other hand, Ab
and P-tau are produced independently of viral DNA replication
then current antiviral agents might not completely inhibit the
production of these proteins, and thus might have a limited effect
on disease progression. The aim of the present study was to
determine the stage of the virus replication cycle necessary for the
accumulation of Ab and P-tau and to determine whether antiviral
agents do reduce the accumulation of Ab and P-tau. Using HSV1
recombinants, we show that Ab and P-tau accumulation requires
the initiation of early and/or late protein synthesis. We found also
that antiviral agents indeed reduce the accumulation of Ab and P-
tau in HSV1-infected cell cultures – supporting the usage of
antiviral agents to treat AD.
Results
Ab and P-tau accumulation requires early and/or late
HSV1 protein synthesis
The infectious cycle of HSV1 is a complex process, which
begins with binding of the virus to heparan sulfate proteoglycan
molecules on the cell surface. Subsequently the virus binds to more
specific receptors which facilitate virus entry into the cell by fusion
[15]. Once inside the cell the virus uncoats, the viral DNA moves
to the nucleus and circularises, and virus gene expression occurs.
Gene expression is initiated by a protein complex consisting of a
viral protein (virion protein (VP16)) and two cellular proteins (host
cell factor 1 and octomer-binding protein 1 (oct1)) [16]. There are
three main classes of genes which are expressed at different times
during infection, and are termed immediate early (IE), early and
late (or alpha, beta and gamma) [17]. IE proteins include infected
cell polypeptide (ICP) 0 and ICP4 which are transcriptional
activators [18,19]. Early proteins include those proteins required
for viral DNA replication such as the protein expressed from the
unique long 42 (UL42) gene [20]. Late proteins include
components of the virus particle such as glycoprotein C (gC)
and proteins required for virus assembly and egress. Expression of
gC is strictly dependent upon viral DNA synthesis [21]. Once
sufficient levels of virion proteins accumulate, virus particles
assemble and the virus exits the cell. Ab and P-tau accumulation
might require any of the stages or components of the infectious
cycle of HSV1.
In order to find which stage of the infection cycle is involved in
the production of Ab and P-tau, we used HSV-1 recombinants
blocked at early stages in the infection cycle. in1374 is a multiple
recombinant that enters cells and is uncoated but does not
synthesise any HSV1 proteins to detectable levels in most infected
cells [22]. Infection of Vero cells with this recombinant, at the
restrictive temperature, did not result in accumulation of Ab or P-
tau (Figure 1A and 2A), whereas infection with the wild-type (WT)
virus in1863 did cause Ab and P-tau accumulation (Figure 1B and
2B). Recombinant tsK/lacZ, a virus with a temperature-sensitive (ts)
mutation in ICP4, at the restrictive temperature expresses IE
proteins at high levels but does not synthesize subsequent early or
late proteins [23]. This recombinant did not show Ab or P-tau
accumulation (Figure 1C and 2C). These results suggest that
neither binding and entry of HSV1 nor the production of IE
proteins is sufficient to cause accumulation of Ab and P-tau. Their
accumulation therefore requires the production of early and/or
late HSV-1-specified proteins.
A viable HSV1 recombinant that specifies a truncated
glycoprotein E (gE) (in1404), and fails to assemble a functional
Fc receptor [24], did produce Ab and P-tau accumulation
(Figure 1D and 2D), suggesting that the Ab and P-tau staining
we observe is not an artefact due to the binding of the primary or
secondary antibodies to the gE-glycoprotein I Fc receptor encoded
by HSV1.
The efficiency of infection with in1863, tsK/lacZ and in1374 was
investigated by staining monolayers for the presence of b-gal. In
cultures infected with in1863 or tsK/lacZ, most cells were positive
for the enzyme (Figure 1 G and H). This demonstrates efficient
primary infection at MOI 5, since tsK/lacZ does not replicate at
the nonpermissive temperature of 38.5uC. Few cells expressed
detectable levels of b-gal in in1374-infected cultures (Figure 1 I).
However, many more were positive for b-gal after co-infection
with WT HSV1 lacking a lacZ insertion (Figure 1 J), because co-
infection provided functional VP16, ICP0 and ICP4.
Inhibition of HSV1 DNA replication reduces the
accumulation of Ab and P-tau in HSV1-infected cells
We investigated whether HSV1 DNA replication was
necessary for the accumulation of Ab and P-tau by using the
antiviral agent acyclovir (ACV), which inhibits HSV1 DNA
replication. ACV targets specifically cells that contain replicating
HSV1 in that its action requires phosphorylation by the viral
thymidine kinase (TK), a more effective phosphorylating agent
than cellular purine or pyrimidine kinases. The monophosphate
form of ACV is then further phosphorylated by cellular kinases
to the active triphosphate form, which has a greater affinity for
viral than for cellular DNA polymerase. Acyclo-GTP is
incorporated into viral DNA, causing chain termination; thus
virus replication and spread are aborted and consequent tissue
damage is halted.
We infected Vero cells with HSV1 at a multiplicity of infection
(MOI) of 1 and examined the effects of varying doses of ACV on
HSV1, Ab and P-tau by immunocytochemistry (ICC). Figures 3,
4 and 5 clearly show a reduction in amounts of HSV1 proteins,
Ab and P-tau in the presence of ACV. Also, at 200 mM ACV the
cells exhibit far less cytopathology. Quantification of these ICC
results using Image J reveals that there is a significant reduction
in HSV1 proteins and abnormal tau phosphorylation at all
concentrations used (p,0.0001 in both cases) and in Ab at
100 mM and 200 mM( p ,0.0001) (Figure 6). The staining for P-
tau dropped to almost zero at 50 mM, but that of Ab decreased
less: at 200 mM ACV its level was 28% of the infected cell value in
the absence of antiviral, significantly different (p,0.05) from the
value for mock-infected cells, which corresponded to about 10%
of the infected cell value.
Similarly, ACV treatment did not cause HSV1 staining to
disappear completely. This might reflect the possibility that the
HSV1 strain we used was ACV-resistant, or that the staining was
caused by proteins produced independently of viral DNA
replication. Therefore the reduction of Ab to only 28% might
be related also to the use of an ACV-resistant strain or to the
possibility that it is produced independently of viral DNA
replication. We checked that the strain of virus we were using
was not resistant to some extent to the antiviral agent using plaque
reduction assay (PRA) to determine the dose of ACV which
reduces infectivity to 50% (IC50). In this method, 24-well plates
were seeded with Vero cells, HSV1 was added and the spread of
the virus was restricted to two dimensions by the use of a dense
medium which results in the formation of plaques (holes within the
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to produce a number of plaques that is easy to count (usually
around 80 plaques per well). Addition of an antiviral agent
reduces the number of plaques per well and, if several doses of
antiviral are used, the IC50 can be determined. Using PRA we
found that the IC50 value of ACV was 0.83 mM, which is
consistent with published values [25], and suggests that the strain
of HSV1 we used was not resistant to ACV. An alternative
explanation for why HSV1 staining did not disappear completely
could be because the antibody we used detected multiple HSV1
proteins. Thus the staining detected might represent proteins that
are expressed independently of viral DNA replication. Therefore
we looked at the effects of ACV on specific HSV1 proteins using
monoclonal antibodies specific for ICP0, UL42 and gC, which
represent proteins from the immediate early, early and late stages,
respectively, of the virus infectious cycle. We found that staining
for gC (a late protein that is dependent on DNA replication) was
reduced to less than 1% of the value in the absence of antiviral,
whereas staining for ICP0 (an IE protein) and UL42 (an early
protein), which are independent of viral DNA replication [17],
was reduced but not to the same extent (to ,20% in each case –
data not shown). This shows that the HSV1 staining occurring
even at high ACV doses presumably reflects these and other
proteins that are synthesised independently of viral replication,
Figure 1. Initiation of Ab accumulation requires the initiation of early and/or late protein synthesis. Vero cells were infected for 16
h o u r sw i t hH S V 1s t r a i n1 7o rw i t hH S V 1r e c o m b i n a n t s ,e a c ha ta nM O Io f5 ,a n dt e s t e df o rA b by immunocytochemistry. Infection with in1374
did not lead to Ab accumulation (A) whereas infection with wild type HSV-1 (in1863) did show Ab accumulation (B). Infection with recombinant
tsK/lacZ showed no Ab accumulation at the restrictive temperature (C). Infection with recombinant in1404 did show Ab staining (D). Mock-
infected cells at 37uC( E )o ra t3 8 . 5 uC (F) showed no staining. Scale bar: 50 mm. To confirm infection of cells, monolayers were stained for the
expression of b-gal. Infection with in1863 (G) or tsK/lacZ (H) resulted in b-gal expression in most cells. In cultures infected with in1374 only a
small proportion of cells expressed b-gal (I), whereas many more were positive after co-infection with in1 3 7 4a n dW TH S V 1( M O I5f o re a c h
virus), demonstrating that in1374 had entered a high proportion of cells (J). Cells show typical HSV1-cytopathic effects, i.e., they become
rounded and contracted.
doi:10.1371/journal.pone.0025152.g001
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replication.
Other antiviral agents produce effects similar to those of
ACV
To discover whether other antiviral agents affect Ab and P-tau
accumulation, we investigated penciclovir (PCV) and foscarnet
(FOS). PCV, another guanine analogue, like ACV depends on the
presence of the HSV1 TK, and its products block chain elongation
of the viral DNA, but the two agents differ in their affinity for TK
and the viral DNA polymerase: that of ACV is much greater for
the TK, and that of PCV (as triphosphate) is much greater for the
polymerase [26]. FOS acts by inhibiting the pyrophosphate
binding site on viral DNA polymerases, at levels that do not affect
human DNA polymerases [27].
Both PCV and FOS reduced accumulation of Ab (Figure 7A).
The decreases in Ab level were statistically significant at all
concentrations of PCV used (p,0.0001) whereas FOS reduced Ab
levels significantly only at 200 mM( p ,0.0001). Comparison of the
different antiviral agents reveals that for Ab levels, at a
concentration of 50 mM the reduction caused by PCV was
significantly different from those of the other antiviral agents
(p=0.025); at 100 mM, the reductions caused by PCV and ACV
were significantly different from that of FOS (p=0.003), but at
200 mM, there were no significant differences amongst the
antiviral agents. Consistently, the concentration of antiviral agent
required to reduce the ICC signal of Ab to 50% was lowest for
PCV (40.8 mM), followed by ACV (84.4 mM) and then FOS
(135.3 mM).
PCV and FOS reduced P-tau level too. The decreases in P-tau
level were statistically significant at all concentrations of PCV used
(p,0.0001) whereas FOS reduced P-tau levels significantly at
100 mM and 200 mM (p=0.012). However, there were no
significant differences in P-tau staining amongst the antiviral
agents at each concentration. Consistently, the concentrations of
antiviral agents required to reduce the ICC signal of P-tau to 50%
were fairly similar for ACV (26.1 mM), PCV (37.6 mM) and FOS
(48.9 mM).
HSV1 levels were statistically significantly reduced at 100 mM
and 200 mM PCV (p,0.0001) but not at any concentration of
FOS (p=0.182). The difference in HSV1 protein staining amongst
the antiviral agents at 50 mM was not significant (p=0.139). At
100 mM and 200 mM the differences were statistically significant
(p=0.001 and p=0.005, respectively), with PCV and ACV
causing a greater reduction than FOS. Consistently, the
concentrations of ACV and PCV required to reduce the ICC
signal of HSV1 proteins to 50% were similar (86.1 mM and
84.5 mM, respectively) and FOS was lower (.200 mM).
These results show that FOS is less effective than ACV or PCV
not only at reducing HSV1 replication but also at reducing Ab and
P-tau production.
As with ACV, PCV reduced P-tau staining to levels similar to
those in mock-infected cells (Figure 7B) but Ab level reached a
plateau of ,20% (Figures 7A), which was statistically significantly
Figure 2. Initiation of abnormal tau phosphorylation requires the initiation of early and/or late protein synthesis. Vero cells were
infected for 16 hours with HSV1 strain 17 or with HSV1 recombinants, each at an MOI of 5, and tested for abnormal tau phosphorylation (pS214) by
immunocytochemistry. Infection with in1374 did not lead to abnormal tau phosphorylation (A) whereas infection with in1863 did show
phosphorylation (B). Infection with recombinant tsK/lacZ showed no abnormal tau phosphorylation at the restrictive temperature (C). Infection with
recombinant in1404 did show staining (D). Mock-infected cells at 37uC (E) or at 38.5uC (F) showed no staining. Scale bar: 50 mm.
doi:10.1371/journal.pone.0025152.g002
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ACV, we used PRA to check that the strain of HSV1 was not
resistant to PCV. We found that the IC50 for PCV was 7.2 mM,
indicating that the strain was not PCV-resistant. We investigated
also the effects of PCV on HSV1 ICP0, UL42 and gC and found
similar results (data not shown) to those of ACV, suggesting again
that Ab production is produced independently of HSV1 DNA
replication.
In the case of FOS treatment, P-tau and Ab were reduced to
,15% and ,20%, respectively (Figures 8A and 8B). We
examined the effects of FOS on HSV1 gC, UL42 and ICP0.
FOS reduced the levels of all these proteins but in all cases the
levels did not decrease to the levels found in mock-infected cells
(data not shown). This might reflect the use of a FOS-resistant
strain of HSV1 (the IC50 in PRA was .100 mM but this is
consistent with published values), the poor antiviral ability of FOS
and/or DNA replication-independent accumulation.
Comparison of quantitative immunocytochemistry with
HSV1 ELISA
As quantitative ICC (qICC) is not a standard method, we
compared the results of the qICC for HSV1 proteins with HSV1
ELISA (PRA could not be used as conditions comparable to qICC
(i.e., an MOI of 1, and 16 hours infection would be unsuitable as
at this dose, plaque numbers would be vastly too high). HSV1
ELISA revealed that the IC50 values for ACV, PCV and FOS
were 81.6 mM, 183 mM and .200 mM, respectively. These
ELISA values are in agreement with those obtained by qICC,
confirming the validity of the latter.
Figure 3. Acyclovir inhibits HSV1 replication. Vero cells were infected with HSV1 SC16 at an MOI of 1 for 16 hours. Cells were treated with 0 mM,
50 mM, 100 mM or 200 mM acyclovir (ACV), which was present throughout infection. After fixation the slides were tested for HSV1 proteins using
immunocytochemistry. Reactivity with HSV1 proteins was significantly reduced in the presence of ACV. Scale bar: 50 mm.
doi:10.1371/journal.pone.0025152.g003
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involved in accumulation of Ab and P-tau in HSV1-
infected cells
HSV1 infection increases the levels of enzymes (or components
of the enzymes) involved in Ab and P-tau formation [7]. We
therefore examined the effects of the antiviral agents on these
levels and found that the virus-induced increases in the Ab-related
enzyme, b-site amyloid precursor protein cleaving enzyme 1
(BACE1), and a component of the c-secretase, nicastrin, were
reduced upon treatment with the antiviral agents (Figure 8).
Quantification of these results showed that FOS is less effective
than ACV and PCV at reducing BACE1 and nicastrin (Figure 9).
Consistently, the concentrations of ACV, PCV and FOS required
to reduce staining to 50% were 46.9, 35.1 and .200 mM for
BACE1 and 54.1, 69.9 and .200 mM for nicastrin. Interestingly,
values for BACE1 and nicastrin did not drop to the levels obtained
for mock-infected cells (which were 0-10% for both BACE1 and
nicastrin).
Similarly the HSV1-induced increases in the P-tau-related
enzymes, protein kinase A (PKA) and glycogen synthase kinase 3b
(GSK3b), are reduced after treatment with ACV, PCV and FOS
(Figure 10). Quantification of the results revealed that FOS is less
effective than ACV and PCV at reducing PKA and GSK3b
(Figure 9). GSK3b staining dropped to levels found in mock-
infected cells (which were 10-20% of the HSV1-infected, no
antiviral values) at 100 mM ACV, 50 mM PCV and 200 mM FOS,
and PKA staining dropped to the levels found in mock-infected
(which were ,20% of the HSV1-infected, no antiviral values) at
Figure 4. Acyclovir inhibits HSV1-induced b-amyloid accumulation. Vero cells were infected with HSV1 SC16 at an MOI of 1 for 16 hours.
Cells were treated with 0 mM, 50 mM, 100 mM or 200 mM acyclovir (ACV), which was present throughout infection. After fixation the slides were tested
for b-amyloid (Ab) accumulation using immunocytochemistry. These results clearly show that ACV reduces Ab significantly. Scale bar: 50 mm.
doi:10.1371/journal.pone.0025152.g004
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treatment did decrease, but did not fall to levels for mock-infected
cells even at 200 mM. The concentrations of ACV, PCV and FOS
required to reduce staining to 50% were 60.7, 47.9 and 136.4 mM
for PKA and 33.4, 26.5 and 94.7 mM for GSK3b.
Discussion
Our main findings are that the three antiviral agents we studied
significantly reduced the levels of Ab and P-tau and inhibited too
the replication of HSV1. Our data using the recombinant viruses
suggest that initial events in the infectious cycle of HSV1, such as
entry, fusion and uncoating, are not sufficient to induce the
accumulation of Ab nor are they sufficient for phosphorylation of
tau at pS214. They show also that none of the IE proteins is
directly responsible for these effects since the IE proteins
accumulate to high levels during infection with the tsK
recombinant but Ab and P-tau are not formed, although we
cannot rule out the possibility that functional ICP4 proteins are
directly needed. Therefore the results with the recombinants
suggest that Ab and P-tau are produced after the IE stage of the
replication cycle of HSV1.
Our results with the antiviral agents suggest that P-tau
formation (as shown by the AT100 antibody) is dependent on
viral DNA replication directly or on a protein that depends on
viral DNA replication, as treatment with ACV and PCV reduced
the AT100 antibody staining to a very low level (,1%).
Consistently, staining for gC, a viral protein that is known to be
dependent on viral DNA replication, was reduced to less than 1%
after treatment with ACV and PCV. FOS did not produce a
Figure 5. Acyclovir inhibits HSV1-induced abnormal tau phosphorylation. Vero cells were infected with HSV1 SC16 at an MOI of 1 for 16
hours. Cells were treated with 0 mM, 50 mM, 100 mM or 200 mM acyclovir (ACV), which was present throughout infection. After fixation the slides were
tested for abnormal tau phosphorylation (AT100) using immunocytochemistry. ACV significantly reduces AT100 staining. Scale bar: 50 mm.
doi:10.1371/journal.pone.0025152.g005
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reflects the fact that FOS is not as effective as ACV and PCV at
inhibiting viral DNA replication. Consistently, ACV and PCV
treatment led to a drop in the staining for the relevant
phosphorylating enzymes – PKA and GSK3b – to levels similar
to those in mock-infected cells.
In contrast to P-tau, Ab accumulation was not completely
inhibited by antiviral treatment; even at a high dose (200 mM)
there was still accumulation which was around 20–30%
(depending on the agent used) of the amount in the absence of
antiviral, a value statistically significantly different from those for
mock-infected cells. Although our results do not preclude higher
doses preventing Ab accumulation completely, the fact that the
staining level of Ab is beginning to plateau with both ACV and
PCV, and that staining of gC and of P-tau was reduced by the
antiviral agents to less than 1%, suggests that Ab is indeed
produced independently of viral DNA replication. Accumulation
of Aa ˆ was inhibited by ACV to approximately the same extent
(70–80%) as production of the IE protein ICP0 and the early
protein UL42. Synthesis of HSV1-specified IE and early proteins
is not affected by inhibition of viral DNA synthesis, therefore we
can infer that about 20–30% of cells were primarily infected and
that the ACV-mediated reduction in ICP0, UL42 and Aa ˆ was due
to prevention of subsequent virus production and spread. We can
infer also that Ab accumulation cannot be a result of virus binding
to the cell surface or of its entry, as it was not caused by the in1374
recombinant virus, which binds to and enters cells but does not
progress further. Further, Ab accumulation cannot be a direct
effect of the IE proteins as it was not produced by infection with
the tsK/lacZ recombinant at the restrictive temperature, which
synthesises IE proteins but progresses no further. Instead it must
be due to an early and/or a late protein (one not dependent on
DNA replication). Consistent with the Ab staining, the staining of
the Ab-related enzymes, BACE1 and nicastrin, did not decrease to
the levels found in mock-infected cells, suggesting that they too are
induced independently of viral DNA replication; however, we did
not investigate their levels with the recombinant viruses, so we
cannot deduce what stage or protein(s) is responsible for their
increase.
Two other groups have recently investigated HSV1-induced Ab
accumulation. Firstly, Piacentini et al. [9] showed that Ab
accumulation occurs in HSV1-infected primary cultures of rat
embryonic neurons. They used also UV-inactivated HSV1 (which
binds to and enters cells but does not replicate) and found that it
did not produce Ab. This is consistent with our results with the
recombinant strains of HSV1. Secondly, Santana et al. [10] found
that in HSV1-infected amyloid precursor protein-transfected
human neuroblastoma cells, Ab accumulation occurred, consistent
with our data, but they detected it two hours post infection, well
before the start of viral DNA replication. Our non-detection of Ab
production at such an early time might have been due to our using
a much lower HSV1 dose – 1 plaque-forming unit (pfu)/cell –
than their 10 pfu/cell, and/or to a cell type difference: we used
non-APP-transfected Vero cells. Another difference is our finding
that FOS decreased Ab levels whereas in their study it did not
visibly affect Ab staining, even at the high concentration of
1.3 mM, although it presumably reduced or stopped viral
replication and spread during the 18 hour infection. This too
might be related to their higher viral dose: theirs would have
infected 100% of cells compared to our 20–30%, thus producing
far more Ab, so that neither FOS, a relatively inefficient inhibitor
of Ab, nor the subsequent stoppage of viral replication would have
had an appreciable effect on Ab level.
Two other studies have investigated the effect of an antiviral on
processes relating to those occurring in AD. Zambrano et al.
showed that in mouse primary neuronal cultures, 50 mM ACV
prevented the neuronal death and neurite disruption induced by
HSV1 [8]. Lukiw et al. investigated the effect of ACV on
miRNA146a, an miRNA implicated as a negative regulator of the
innate immune system in AD and several other diseases, and
found that 30 mM ACV significantly countered the increase in
level of the miRNA caused by HSV1 [28]. These results support
our findings in showing that an antiviral agent can reduce or
eliminate the adverse effects of HSV1 on cells, in particular those
Figure 6. Quantification of HSV1 proteins, b-amyloid and
abnormal tau phosphorylation in HSV1-infected cells after
acyclovir treatment. Vero cells were infected with HSV1 SC16 at an
MOI of 1 for 16 hours. Cells were treated with 0 mM, 50 mM, 100 mMo r
200 mM acyclovir (ACV), which was present throughout infection. After
fixation the slides were tested for HSV1 proteins, b-amyloid (Ab)
accumulation and abnormal tau phosphorylation (AT100) using
immunocytochemistry and the amount of staining was quantified
using Image J. Values are expressed as a percentage of staining
produced when no antiviral is used. For HSV1 proteins (A) and
abnormal tau phosphorylation (C), there is a statistically significant
decrease in staining for all concentrations of ACV tested compared to
the staining in cells infected but not treated with ACV (p,0.0001 in
both cases). For Ab (B), there is a statistically significant decrease in
staining with 100 mM ACV and 200 mM only (p,0.0001). ANOVA was
used to test for significance. The results are a combination of two
independent experiments.
doi:10.1371/journal.pone.0025152.g006
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contention that antiviral agents should be used for treating AD.
However, we should stress, as we did in a recent review [29], that
there are obvious limitations in comparing data on lytic infection
of Vero cells with the changes seen in long-term neurodegener-
ative disease, just as there are limitations in deducing what changes
occur in brain in early stage AD (few of which, obviously, are
known) from the changes seen post mortem.
As well as the data supporting the role of HSV1 in AD, other
researchers have argued against its role in the disease. One
argument proffered is that HSV1 is too common to be involved.
However, HSV1 infection is common only in the peripheral
nervous system: at least 80% of the population have been infected
with HSV1 by age 60 (previously, primary infection usually
occurred in early infancy but with increasing socio-economic
levels, it often now occurs at a later age). In contrast in the brain, it
is usually absent in younger people: using solution PCR, we
detected HSV1 DNA in many elderly brains but only in very few
younger brains [30], and these results were substantiated by in situ
PCR [14] and a totally different method, namely, detection of
Figure 7. Comparison of different antiviral agents on proteins accumulating during HSV1 infection. Vero cells were infected with HSV1
SC16 at an MOI of 1 for 16 hours. Cells were treated with 0 mM, 50 mM, 100 mM or 200 mM penciclovir (PCV) or foscarnet (FOS) which was present
throughout infection. After fixation the slides were tested for (A) b-amyloid (Ab) accumulation, (B) abnormal tau phosphorylation (AT100), and (C)
HSV1 proteins using immunocytochemistry and the amount of staining was quantified using Image J. Values are expressed as a percentage of
staining produced when no antiviral is used. These values were used to determine the antiviral concentration required to reduce staining to 50%. The
results are a combination of two independent experiments. Values for mock-infected cells were between 0 and 8% (data not shown).
doi:10.1371/journal.pone.0025152.g007
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infants [31]. Subsequently, the presence of HSV1 in the human
brain was confirmed by several other groups (reviewed in [32]),
using solution PCR. However, two studies found HSV1 DNA only
very rarely in human brains [33,34] and we have discussed the
possible reasons for this [35,36].
Another argument, against the role of HSV1 in AD is the lack of
confirmatory studies showing that the combination of HSV1 in
brain and possession of an APOE-e4 allele is a strong risk factor
for AD. In fact there is one study that showed consistent results [4]
and a second that found a trend towards association [37]. No other
relevant studies have been published. Also, in support of the
HSV1-APOE connection are the studies showing that APOE-e4
confers a strong risk of herpes labialis, a disorder of the peripheral
nervous system known to be caused (usually) by HSV1 [3,38] and
also the studies showing the greater potential for HSV1 damage in
infected APOE-e4-transgenic mice compared to infected APOE-
e3 mice (reviewed in [32]).
A further argument against the role of HSV1 in AD is that Ab
and P-tau accumulation are not specific to HSV1. Indeed, other
pathogens can produce AD-like changes – for example HIV causes
Ab and P-tau formation [39–41], and measles virus causes
neurofibrillary tangles formation [42], but currently only HSV1,
unlike these other viruses, has been detected in normal or AD
brains, and so is the only candidate agent.
As well as undergoing a productive infection, HSV1 can
undergo a latent infection in which no viral particles are produced
and HSV1 gene expression is limited. However, stimuli such as
stress and immunosuppression can reactivate the virus, leading to
a productive infection. We have suggested that in later life the
virus spreads to and becomes latent in the brain, and that during
events such as immunosuppression, head trauma and peripheral
infections, the virus reactivates and causes damage, including Ab
and P-tau formation. After each reactivation event, we suggest that
HSV1 would spread (via intraneuronal pathways) and would thus
become latent in additional cells. Repeated reactivation would
lead to further spread and cumulative damage, which would
develop into AD in those who possess an APOE-e4 allele. Our
concept of repeated reactivation is supported by the very recent
finding that in infected mice, stimuli that induce HSV1
reactivation in the peripheral nervous system can cause it also in
the brain, and that although virus production is limited to small
regions, periodic reactivation induces areas of ‘‘focal reactive
changes’’ [43]. Further, a repeated occurrence, rather than a
single acute event, meets the requirement for a slow chronic
disease.
Figure 8. Antiviral agents reduce the HSV1-induced increases in b-amyloid-related enzymes. Vero cells were infected with HSV1 SC16 at
an MOI of 1 for 16 hours. Cells were treated with 0 mM, 50 mM, 100 mM or 200 mM acyclovir (ACV), penciclovir (PCV) or foscarnet (FOS) which was
present throughout infection. After fixation the slides were tested for (A) b-site amyloid precursor protein cleaving enzyme 1 (BACE1) and (B)
nicastrin. Images for no antiviral, 50 mM ACV, 50 mM PCV and 200 mM FOS are shown. Scale bar: 50 mm.
doi:10.1371/journal.pone.0025152.g008
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of AD. Although our results show that the antiviral agents we used
did not stop Ab accumulation completely, there was a statistically
significant decrease. This decrease presumably reflects the
inhibition of virus spread, which occurs as a consequence of the
antiviral agents’ effect on viral DNA replication, i.e., stopping viral
DNA replication prevents complete virions from being formed and
therefore stops the virus from spreading to additional cells.
Therefore, our results suggest that antiviral agents, by preventing
HSV1 spread as well as its replication, would provide effective
treatment for the disease.
Our results suggest that ACV or PCV would be more suitable
that FOS for use in AD since FOS was less effective at inhibiting
HSV1replication (consistentwithearlierstudieswith thisagent)and
P-tau formation. A major consideration in the choice of an antiviral
agentwouldbeitsabilitytopreventorreduceHSV1reactivation,as
well as to reduce production of Ab and P-tau. On that basis, PCV
might provide a better alternative as some studies suggest that it can
reduce the frequency or extent of HSV1 reactivation [44-46]. Also,
althoughthe differences inaffinityofACVand PCVforTKand the
viral DNA polymerase, as mentioned above, probably balance each
other, the intracellular half-life of the PCV triphosphate in infected
cells is about 14 times that of ACV [26], suggesting that for clinical
use, less frequent dosage might be needed.
Usage of an anti-herpetic such as ACV, or its biodrug
valacyclovir (VCV), which has better oral bioavailability, to
treat AD could prevent direct viral damage and, indirectly,
HSV1-induced inflammation), irrespective of whether or not Ab
is involved. Clearly it would be preferable to start such
treatment at as early a stage of the disease as possible when it
is suspected in subjects with mild cognitive impairment. Another
issue to consider is how effectively ACV would get to the brain
in AD. However, this appears not be problematic since in
people with normal blood-CSF barrier function, including those
who have recovered from HSE, ACV (derived from VCV) has
been shown to be present in CSF at the inhibitory level for
HSV1 [47,48].
The most usual target for current therapy is the elimination of
Ab production. However, if Ab is in fact formed as an innate
immune response but presumably – as we have suggested [32] –
over-produced eventually, with consequent harmful effects, then
its elimination might well be counter-productive. We therefore
stress that antiviral agents would have an advantage in not
eliminating Ab but instead reducing it to a level closer to its
normal very low value, which is approximately 10% of the HSV1-
infected value. This could perhaps be achieved by using either
another antiviral with a different mode of action that is more
efficient than ACV or a combination of two antiviral agents
operating via different mechanisms. Further, we stress that
antivirals used in the current study are very safe and unlike other
types of therapy, would not target any substance normally
produced by the cell.
Figure 9. Quantification of the effect of antiviral agents on the HSV1-induced increases in amyloid- and tau-related enzymes. The
immunocytochemistry results in Figures 8 and 9 were quantified using Image J. (A) b-site amyloid precursor protein cleaving enzyme 1, (B) nicastrin,
(C) protein kinase A and (D) glycogen synthase kinase 3b.
doi:10.1371/journal.pone.0025152.g009
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Viruses, cells and antiviral agents
We used HSV1 strain SC16, which was prepared as previously
described [49], and HSV1 strain 17. Four derivatives of strain 17
were also used. Recombinant in1404 has an 8 base pair (bp)
insertion in a HpaI site within the coding region of gE such that a
termination codon was generated after codon 124 of the gE
coding region. The mutant is predicted to synthisize a severely
truncated protein, and cells infected with in1404 fail to bind
rabbit IgG, indicatin that functional gE is not present [24].
Recombinant tsK/lacZ has a ts mutation in the coding sequences
of ICP4 [23,50], and in addition the virus used here has an
insertion of the E.coli lacZ coding sequences controlled by the
human cytomegalovirus major immediate early promoter (MIEP
and simian virus 40 polyadenylation sequences inserted at the
thymidine kinase (TK) locus). Insertion of the MIEP-lacZ cassette
was achieved by co-transfection of ScaI-cleaved pMJ101 with tsK
DNA, using methods described previously [51]. Plasmid pMJ101
consists of the MIEP-lacZ cassette inserted at SacI site within the
TK coding region. ACV-resistant isolates were plaque purified
and screened by Southern hybridization for disruption of a 2.4
kilobase pair EcoRI fragment that encompasses the TK coding
sequences [51]. The recombinant in1863 was produced by co-
transfection of ScaI-cleaved pMJ101 with DNA of 1814R,
anHSV1, strain 17, isolate that is analogous to WT virus
[52], using the methods described above for the construction of
tsK/lacZ.
Recombinant in1374 has the ts mutation in ICP4, a deletion
that inactivates the IE protein ICP0, an insertion that prevents
stimulation of IE transcription by the HSV1 virion protein VP16,
and the MIEP-lacZ insertion at the TK locus [22]. During
infection at 38.5uC, tsK/lacZ produces IE proteins and beta-
galactosidase (b-gal) but does not synthesize early or late proteins,
whereas in1374 enters cells but does not produce detectable
amounts of HSV1-specified gene products or b-gal in most
infected cells [22]. Insertions of MIEP-lacZ were confirmed by
Southern hybridization. The presence of the ICP4 ts mutation in
tsK/lacZ and in1374 was confirmed by comparison of titres at
32uC and 38.5uC. The titre of in1374 was determined on the
human osteosarcoma line U2OS at 32uC, in the presence of
3 mM hexamethylene bisacetamide. Under these conditions, the
mutations in ICP4, ICP0 and VP16 are complemented, as
described previously [22]. The other strain 17-derived viruses were
titrated on baby hamster kidney (BHK-21) cells. The properties of
the strain 17-derived viruses are summarised in Table 1. Staining
for the presence of b-gal, and counterstaining of cells, were carried
out as described previously [51].
Figure 10. Antiviral agents reduce the HSV1-induced increases in tau-related enzymes. Vero cells were infected with HSV1 SC16 at an
MOI of 1 for 16 hours. Cells were treated with 0 mM, 50 mM, 100 mM or 200 mM acyclovir (ACV), penciclovir (PCV) or foscarnet (FOS) which was present
throughout infection. After fixation the slides were tested for (A) protein kinase A (PKA) and (B) glycogen synthase kinase 3b (GSK3b). Images for no
antiviral, 50 mM ACV, 50 mM PCV and 100 mM FOS are shown. Scale bar: 50 mm.
doi:10.1371/journal.pone.0025152.g010
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Agency Culture Collections, Salisbury, UK) were cultured in
Eagles modified essential medium containing non-essential amino
acids, 10% foetal bovine serum, 4 mM glutamine, 10,000 U/ml
penicillin and 10 mg/ml streptomycin. Cells were sub-cultured
using trypsin-EDTA solution (T3924, Sigma-Aldrich).
ACV and FOS were purchased from Sigma-Aldrich, and PCV
from VWR.
Immunocytochemistry
For the experiments involving the recombinant viruses, Vero
cells were seeded on to slides coated with 3-aminopropyltriethox-
ysilane, infected with HSV1 strain17 for 20 hours at an MOI of 5
and then fixed in phosphate-buffered saline (PBS) containing 4%
formaldehyde and 10% acetic acid. For the experiments involving
antiviral agents, 3-aminopropyltriethoxysilane-coated slides were
seeded with 1.13610
6 Vero cells per slide and left overnight
to settle. HSV1, at a MOI of 1, and ACV, PCV or FOS (at
various doses) were then added. After 16 hours incubation, the
cells were fixed in PBS containing 4% formaldehyde and 10%
acetic acid.
Subsequently, slides were washed twice in Tris-buffered saline
(TBS) for 5 minutes and then in 20% acetic acid to block
endogenous alkaline phosphate activity. (For detection of Ab1-42,
slides had an initial treatment of 70% formic acid for 10 minutes
and a three-minute wash in running tap water for antigen
retrieval). The slides were then washed twice in TBS containing
0.025% Triton X and once in distilled water (each wash lasting
five minutes), before being blocked for 60 minutes at room
temperature in TBS containing 10% skimmed milk or TBS
containing 10% goat serum and 1% bovine serum albumin. After
two five-minute washes in TBS containing 0.025% Triton X,
primary antibody was applied. Slides were incubated overnight at
4uC, washed in TBS containing 0.025% Triton X and biotinylated
secondary antibody was added for 60 minutes. Subsequently, the
slides were washed in TBS containing 0.025% Triton X and then
treated with an avidin-alkaline phosphatase conjugate for 60
minutes before being washed in TBS. Substrate (BCIP/NBT) was
then added until sufficient staining had developed. The primary
antibodies used and their concentrations are shown in Table 2.
Image J analysis
We quantified the ICC staining using the image analysis
software Image J. This software assigns each pixel in the picture of
the staining a value (between 0 and 255) which represents its
brightness. Bright pixels have high values and dark pixels have low
values. A range of pixel-brightness values is selected and any cells
with a staining value lying within the range are regarded as
positive; in the case of ICC the range is all pixels between a certain
value and zero. This range is applied to all pictures of staining with
the same antibody and the values produced represent the number
of pixels showing positive staining.
We counted the number of cells in each field of view (using a
phase-contrast image of the field) and used this value to determine
the amount of ICC staining per cell. For each antibody we
analysed three fields of view and used ANOVA to assess statistical
Table 1. Properties of HSV1 strain 17-derived viruses.
Virus Changes from WT HSV1 Properties Reference
in1863 Insertion of MIEP-lacZ at TK locus WT virus that expresses b-gal
in1404 Insertion of 8 bp oligonucleotide in gE coding sequences Does not express functional gE [24]
tsK/lacZ ts mutation in ICP4, insertion of MIEP-lacZ at TK locus Overproduces IE proteins and expresses b-gal but does
not synthesize early or late proteins at 38.5uC
[23,50]
in1374 Mutations that inactivate VP16 transactivation function,
ICP0 and ICP4, insertion of MIEP-lacZ at TK locus
Enters cells but synthesizes IE proteins and b-gal in only
a small subset of infected cells
[22]
doi:10.1371/journal.pone.0025152.t001
Table 2. Details of primary antibodies used for immunocytochemistry in this study.
Antigen detected Host Source Product code Dilution of primary Incubation time Secondary used
Amyloid b1-42 Rabbit Abcam ab10148 1 in 250 Overnight Anti-Rabbit IgG
pS214 Rabbit Abcam ab10391 1 in 500 Overnight Anti-Rabbit IgG
AT100 Mouse Autogen Bioclear 90209 1 in 500 Overnight Anti-Mouse IgG
HSV1 Rabbit Abcam ab9533 1 in 1000 Overnight Anti-Rabbit IgG
ICP0 Mouse In house n/a 1 in 1000 Overnight Anti-Mouse IgG
UL42 Mouse In house n/a 1 in 10,000 Overnight Anti-Mouse IgG
gC Mouse In house n/a 1 in 2000 Overnight Anti-Mouse IgG
BACE1 Rabbit Abcam ab2077 1 in 250 Overnight Anti-Rabbit IgG
Nicastrin Rabbit Abcam ab24741 1 in 500 Overnight Anti-Rabbit IgG
PKA Rabbit Abcam ab26322 1 in 2000 Overnight Anti-Rabbit IgG
GSK3b Rabbit Abcam ab15314 1 in 100 10 mins Anti-Rabbit IgG
For the nicastrin and BACE1 antibodies the blocking buffer used was TBS containing 10% goat serum and 1% bovine serum albumin. For the other antibodies 10% milk
was used.
doi:10.1371/journal.pone.0025152.t002
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of the target protein in situ, and so, unlike ELISA and Western
blotting, does not depend on the efficiency of extraction of the
protein, and also, rather than measuring the overall amount of
target protein in or extracted from a presumed number of cells
remaining after treatment, it can measure target protein in
individual cells and the actual cell numbers. Further, this method
overcomes the problems associated with any viral-induced changes
in host cells (e.g., binding and aggregation of host proteins) that
might affect their assay by techniques such as Western blotting and
ELISA.
Plaque reduction assay
24-well plates were seeded with 1.81610
5 Vero cells/well and
the cells allowed to settle overnight. HSV1 was then added at a
dose (0.0004 pfu/cell) that would result in the formation of
approximately 80 plaques per well (i.e. a number that is easily
countable and which would provide also an adequate statistical
baseline). After incubation at 37uC for 1 hour, the HSV1-
containing medium was replaced with medium containing 2%
foetal bovine serum, 0.2% high viscosity carboxymethylcellulose
and ACV, PCV or FOS (at various concentrations). After two
days, cells were fixed with 10% formalin in PBS and stained with
carbol fuchsin. Plaque numbers were counted and the dose of
antiviral required to reduce infectivity to 50% (IC50) was
calculated.
HSV1 ELISA
96-well plates were seeded with 2.20610
4 Vero cells/well and
the cells allowed to settle overnight. Cultures were mock infected
or infected with HSV1 at a dose of 1 pfu/cell and incubated at
37uC for 16 hours. ACV, PCV and FOS (at various concentra-
tions) were present throughout infection. Cells were fixed in
acetone:methanol (1:1) and then blocked with 10% skimmed milk.
After 30 minutes of blocking, the plates were washed three times
with 0.05 % Tween 20 in PBS and the primary antibody (anti-
HSV1, abcam ab9533), diluted 1 in 8000 in blocking buffer, was
applied for 90 minutes at 37uC. Subsequently, the plates were
washed three times with 0.05 % Tween 20 in PBS and the
secondary antibody (rabbit polyclonal to goat IgG HRP-
conjugated (Abcam)), diluted 1 in 5000 in blocking buffer, was
added. Following incubation at 37uC for 90 minutes and a further
three washes with 0.05 % Tween 20 in PBS, peroxidase substrate
(o-phenylenediamine dihydrochloride, Sigma), diluted in urea
buffer, was added. After 30 minutes the reaction was stopped with
3 M hydrochloric acid and the absorbance at 492 nm was
measured. IC50 values were calculated.
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